[Gd@C82(OH)22]n nanoparticles inhibit the migration and adhesion of glioblastoma cells

Wang,Jing; Gu,Feng; Ding,Ting; Liu,Xiaoli; Xing,Gengmei; Zhao,Yuliang; Zhang,Ning; Ma,Yongjie

doi:10.3892/ol_00000135

[Gd@C82(OH)22]n nanoparticles inhibit the migration and adhesion of glioblastoma cells

Authors:
- Jing Wang
- Feng Gu
- Ting Ding
- Xiaoli Liu
- Gengmei Xing
- Yuliang Zhao
- Ning Zhang
- Yongjie Ma
View Affiliations

Affiliations: Central Laboratory of the Oncology Department, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China
Published online on: July 1, 2010 https://doi.org/10.3892/ol_00000135
Pages: 771-775

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In our previous study, [Gd@C82(OH)22]n, a fullerene-based nanoparticle, exhibited potent anti-tumor effects in mouse tumor-bearing models without detectable toxicity. The mechanism involved in the anti-tumor effect exerted by [Gd@C82(OH)22]n remains to be elucidated. This study found that glioblastoma cells treated with [Gd@C82(OH)22]n nanoparticles showed a significant impairment in migration and adhesion by cell chemotaxis, scratch and adhesion assays in vitro. Furthermore, our data showed that the key proteins, CD40 and ICAM-1, were involved in the inhibition of adhesion in the [Gd@C82(OH)22]n nanoparticle-treated glioblastoma cells. Thus, our study suggests that the [Gd@C82(OH)22]n nanoparticle is a new potential anti-tumor effector and a therapeutic component for malignant glioblastoma infiltration.

View Figures

View References

1	Kroto HW, Heath JR, O’Brien SC, Curl RF and Smalley RE: C60: Buckminsterfullerene. Nature. 318:162–163. 1985. View Article : Google Scholar
2	Wang J, Chen C, Li B, et al: Antioxidative function and biodistribution of [Gd@C₈₂(OH)₂₂]_n nanoparticles in tumor-bearing mice. Biochem Pharmacol. 71:872–881. 2006.
3	Cagle DW, Kennel SJ, Mirzadeh S, Alford JM and Wilson LJ: In vivo studies of fullerene-based materials using endohedral metallofullerene radiotracers. Proc Natl Acad Sci USA. 96:5182–5187. 1999. View Article : Google Scholar : PubMed/NCBI
4	Chen C, Xing G, Wang J, et al: Multihydroxylated [Gd@C₈₂(OH)₂₂]_n nanoparticles: antineoplastic activity of high efficiency and low toxicity. Nano Lett. 5:2050–2057. 2005.
5	Anderson SA, Lee KK and Frank JA: Gadolinium-fullerenol as a paramagnetic contrast agent for cellular imaging. Invest Radiol. 41:332–338. 2006. View Article : Google Scholar : PubMed/NCBI
6	Mikawa M, Kato H, Okumura M, et al: Paramagnetic water-soluble metallofullerenes having the highest relaxivity for MRI contrast agents. Bioconjug Chem. 12:510–514. 2001. View Article : Google Scholar : PubMed/NCBI
7	Bolskar RD, Benedetto AF, Husebo LO, et al: First soluble M@C60 derivatives provide enhanced access to metallofullerenes and permit in vivo evaluation of Gd@C₆₀[C(COOH)₂]10 as a MRI contrast agent. J Am Chem Soc. 125:5471–5478. 2003. View Article : Google Scholar : PubMed/NCBI
8	Zhang B, Gu F, She C, et al: Reduction of Akt2 inhibits migration and invasion of glioma cells. Int J Cancer. 125:585–595. 2009. View Article : Google Scholar : PubMed/NCBI
9	Guo H, Gu F, Li W, et al: Reduction of protein kinase c zeta inhibits migration and invasion of human glioblastoma cells. J Neurochem. 109:203–213. 2009. View Article : Google Scholar : PubMed/NCBI
10	Huang J, Chen K, Gong W, Dunlop NM and Wang JM: G-protein coupled chemoattractant receptors and cancer. Front Biosci. 13:3352–3363. 2008. View Article : Google Scholar : PubMed/NCBI
11	Kurosaka S and Kashina A: Cell biology of embryonic migration. Birth Defects Res C Embryo Today. 84:102–122. 2008. View Article : Google Scholar
12	Rorth P: Collective cell migration. Annu Rev Cell Dev Biol. 25:407–429. 2009. View Article : Google Scholar
13	Etienne-Manneville S and Hall A: Integrin-mediated activation of Cdc42 controls cell polarity in migrating astrocytes through PKCzeta. Cell. 106:489–498. 2001. View Article : Google Scholar : PubMed/NCBI
14	Lefranc F, Brotchi J and Kiss R: Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol. 23:2411–2422. 2005. View Article : Google Scholar : PubMed/NCBI
15	Wischhusen J, Schneider D, Mittelbronn M, et al: Death receptor-mediated apoptosis in human malignant glioma cells: modulation by the CD40/CD40L system. J Neuroimmunol. 162:28–42. 2005. View Article : Google Scholar : PubMed/NCBI
16	Li H and Nord EP: CD40/CD154 ligation induces mononuclear cell adhesion to human renal proximal tubule cells via increased ICAM-1 expression. Am J Physiol Renal Physiol. 289:F145–F153. 2005. View Article : Google Scholar : PubMed/NCBI
17	Sumimoto S and Mayumi M: [Role of LFA-1/ICAM-1-dependent cell adhesion in CD40-mediated inhibition of anti-IgM antibody-induced B-cell death]. Nippon Rinsho. 54:1779–1783. 1996.
18	Jain KK: Nanotechnology in clinical laboratory diagnostics. Clin Chim Acta. 358:37–54. 2005. View Article : Google Scholar : PubMed/NCBI
19	Juillerat-Jeanneret L and Schmitt F: Chemical modification of therapeutic drugs or drug vector systems to achieve targeted therapy: looking for the grail. Med Res Rev. 27:574–590. 2007. View Article : Google Scholar : PubMed/NCBI
20	LaRocque J, Bharali DJ and Mousa SA: Cancer detection and treatment: the role of nanomedicines. Mol Biotechnol. 42:358–366. 2009. View Article : Google Scholar : PubMed/NCBI
21	Yin JJ, Lao F, Meng J, et al: Inhibition of tumor growth by endohedral metallofullerenol nanoparticles optimized as reactive oxygen species scavenger. Mol Pharmacol. 74:1132–1140. 2008. View Article : Google Scholar : PubMed/NCBI
22	Roebuck KA and Finnegan A: Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J Leukoc Biol. 66:876–888. 1999.PubMed/NCBI